CD276 and cancer: As cancer antigen escape seems less likely to occur when the cancer driver gene is a target antigen, B7-H3-targeting immunotherapy might be an attractive treatment option for PAX3-FOXO1 positive ARMS, although we did not examine the anti-B7-H3 targeted therapy for ARMS in this study.